Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 10:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 40,448 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Cancer Diagnosis Clear all
Terminated Phase 1 Interventional

Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)

NCT02203773
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Myelogenous Leukemia, Treatment Naive AML
Interventions
Posaconazole, ABT-199, Decitabine, Azacitidine
Drug
Lead sponsor
AbbVie
Industry
Eligibility
60 Years and older
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
13
States / cities
Duarte, California • Sacramento, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated May 15, 2023 · Synced Sep 7, 2026, 10:24 PM EDT
Completed Phase 2 Interventional

Proton Craniospinal Radiation Therapy vs. Partial Photon Radiation Therapy for Leptomeningeal Metastasis From Solid Tumors

NCT04343573
View directory record Official record
Conditions
Leptomeningeal Metastases
Interventions
Involved-field Photon Radiation Therapy, Proton Craniospinal Irradiation (CSI), Neurocognitive Assessment, MDASI-BT and MDASI-SP
Radiation · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Up to 99 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 7, 2026, 10:24 PM EDT
Active, not recruiting Phase 3 Interventional

REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)

NCT05973773
View directory record Official record
Conditions
Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
Interventions
TAS6417
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
9
States / cities
Henderson, Nevada • Las Vegas, Nevada • Canton, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 7, 2026, 10:24 PM EDT
Terminated Phase 2 Interventional Results available

Allogeneic Stem Cell Transplant After ATG, High-Dose Melphalan, and Fludarabine for Patients With Breast Cancer

NCT00074269
View directory record Official record
Conditions
Breast Cancer
Interventions
anti-thymocyte globulin, filgrastim, graft-versus-tumor induction therapy, therapeutic allogeneic lymphocytes, cyclosporine, fludarabine phosphate, melphalan, methotrexate, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2023 · Synced Sep 7, 2026, 10:24 PM EDT
Recruiting Not applicable Interventional

Study to Assess the Impact of the Urine Test Cxbladder Triage Plus on the Number of Cystoscopies Performed on Patients With Invisible Blood in Their Urine.

NCT06394869
View directory record Official record
Conditions
Hematuria - Cause Not Known
Interventions
Cxbladder Triage Plus
Diagnostic Test
Lead sponsor
Pacific Edge Limited
Industry
Eligibility
18 Years to 88 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
20
States / cities
Homewood, Alabama • Mobile, Alabama • Fresno, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 7, 2026, 10:24 PM EDT
Withdrawn Phase 2 Interventional

Lenalidomide in Treating Patients With High-Risk Chronic Lymphocytic Leukemia

NCT01271283
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage IV Chronic Lymphocytic Leukemia
Interventions
Diagnostic Laboratory Biomarker Analysis, Lenalidomide
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Sep 7, 2026, 10:24 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Validation and Scaling of Screening Program for Undiagnosed Myasthenia Gravis-Social Media Campaign Paired With a Self-moderated Assessment

NCT06866483
View directory record Official record
Conditions
Myasthenia Gravis, Neuromuscular Disease, Neuromuscular Manifestations
Interventions
Social media recruitment, Self-Assessment, Follow-up
Behavioral
Lead sponsor
ZS Associates
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 9, 2025 · Synced Sep 7, 2026, 10:24 PM EDT
Completed Not applicable Interventional

PRISM for Depression and Anxiety in Young Adults With Cancer

NCT06502483
View directory record Official record
Conditions
Cancer Diagnosis, Non-Metastatic Neoplasm, Anxiety, Anxiety Disorders, Depression, Depressive Disorder, Depression, Anxiety, Desmoid
Interventions
Promoting Resilience in Stress Management Program
Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 39 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Brighton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 7, 2026, 10:24 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies

NCT01325441
View directory record Official record
Conditions
Cancer
Interventions
BBI608, Paclitaxel
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
565 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
17
States / cities
Los Angeles, California • Denver, Colorado • Indianapolis, Indiana + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Sep 7, 2026, 10:24 PM EDT
Enrolling by invitation No phase listed Observational

Long-Term Follow-up Study

NCT05332054
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin, Relapsed Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Lymphoma, B Cell Lymphoma, B-Cell Non-Hodgkin's Lymphoma, Hematologic Malignancy, Relapsed/Refractory Multiple Myeloma, Relapsed/Refractory Acute Myeloid Leukemia
Interventions
Caribou-sponsored investigational therapy
Biological
Lead sponsor
Caribou Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2041
U.S. locations
31
States / cities
Birmingham, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Sep 7, 2026, 10:24 PM EDT
Withdrawn Not applicable Interventional

First-in-Human Safety Study Of Laser Tissue Welding For Surtureless Laparoscopic Partial Nephrectomy

NCT02061605
View directory record Official record
Conditions
Benign Renal Tumors, Malignant Renal Tumors
Interventions
Laser Tissue Welding Device
Device
Lead sponsor
Laser Tissue Welding, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 5, 2022 · Synced Sep 7, 2026, 10:24 PM EDT
Completed Phase 2 Interventional Results available

Alvocidib and Oxaliplatin With or Without Fluorouracil and Leucovorin Calcium in Treating Patients With Relapsed or Refractory Germ Cell Tumors

NCT00957905
View directory record Official record
Conditions
Recurrent Extragonadal Seminoma, Recurrent Malignant Extragonadal Germ Cell Tumor, Recurrent Malignant Extragonadal Non-Seminomatous Germ Cell Tumor, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Ovarian Germ Cell Tumor, Stage III Testicular Cancer, Stage IV Extragonadal Non-Seminomatous Germ Cell Tumor, Stage IV Extragonadal Seminoma, Stage IV Ovarian Germ Cell Tumor
Interventions
Alvocidib Hydrochloride, Fluorouracil, Leucovorin Calcium, Oxaliplatin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
10
States / cities
Beverly Hills, California • Duarte, California • Los Angeles, California + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced Sep 7, 2026, 10:24 PM EDT
Recruiting Early Phase 1 Interventional

Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma

NCT03719105
View directory record Official record
Conditions
NK-Cell Lymphoma, NK-Cell Leukemia, Peripheral T Cell Lymphoma
Interventions
Methotrexate, pralatraxate,, Ifosfamide, Dexamethasone, Etoposide, calaspargase pegol, cyclophosphamide, Doxorubicin, Prednisone, Brentuximab Vedotin
Drug
Lead sponsor
New York Medical College
Other
Eligibility
1 Year to 31 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
6
States / cities
Birmingham, Alabama • Orange, California • San Francisco, California + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 7, 2026, 10:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Diindolylmethane in Preventing Cancer in Healthy Volunteers

NCT00784394
View directory record Official record
Conditions
Healthy, no Evidence of Disease
Interventions
diindolylmethane, placebo, pharmacological study, laboratory biomarker analysis, quality-of-life assessment
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 28, 2016 · Synced Sep 7, 2026, 10:24 PM EDT
Recruiting No phase listed Observational

Diagnostic Strategies, Risk Assessment and Progression of Pancreatic Cysts

NCT04473794
View directory record Official record
Conditions
Pancreatic Neoplasms, Pancreas Cancer
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2036
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Sep 7, 2026, 10:24 PM EDT
Completed Phase 3 Interventional Results available

Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma

NCT03391466
View directory record Official record
Conditions
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Interventions
Axicabtagene Ciloleucel, Platinum-containing Salvage Chemotherapy, Cyclophosphamide, Fludarabine
Biological · Drug
Lead sponsor
Kite, A Gilead Company
Industry
Eligibility
18 Years and older
Enrollment
359 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
30
States / cities
Gilbert, Arizona • Phoenix, Arizona • La Jolla, California + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2025 · Synced Sep 7, 2026, 10:24 PM EDT
Not yet recruiting Not applicable Interventional

Reach and Engagement of GENetic Education, Risk Assessment, and TEsting Feasibility Trial

NCT07787156
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma (PDAC), Family History of Pancreas Cancer, Genetic Testing, Multi-cancer Early Detection
Interventions
Telephone education session, Online educational materials
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 7, 2026, 10:24 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma

NCT04458922
View directory record Official record
Conditions
Central Chondrosarcoma, Grade 2, Central Chondrosarcoma, Grade 3, Dedifferentiated Chondrosarcoma, Metastatic Clear Cell Sarcoma of Soft Tissue, Metastatic Primary Central Chondrosarcoma, Unresectable Primary Central Chondrosarcoma
Interventions
Atezolizumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
14
States / cities
Los Angeles, California • Gainesville, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 7, 2026, 10:24 PM EDT
Recruiting Phase 1 Interventional

CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia

NCT07464951
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML)
Interventions
Anti-CD123 LV redirected T cells (CART123), Ruxolitinib (JAKAVI®)
Biological · Drug
Lead sponsor
Stephan Grupp MD PhD
Other
Eligibility
0 Years to 29 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 7, 2026, 10:24 PM EDT
Completed Phase 4 Interventional Results available

Preemptive Ethanol Lock Therapy in Pediatric Bloodstream Infection

NCT02095951
View directory record Official record
Conditions
Leukemia, Lymphoma, Blood Disorders, Solid Tumors
Interventions
Ethanol lock therapy (ELT)
Drug
Lead sponsor
Children's Hospital of Michigan
Other
Eligibility
6 Months to 21 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 18, 2018 · Synced Sep 7, 2026, 10:24 PM EDT
Completed Phase 1 Interventional

A Phase I Study of MGCD0103 Given Three-Times Weekly In Patients With Leukemia Or Myelodysplastic Syndromes

NCT00324129
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes
Interventions
MGCD0103
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 7, 2015 · Synced Sep 7, 2026, 10:24 PM EDT
Completed Phase 2 Interventional Results available

Temozolomide in Treating Patients With Low-Grade Glioma

NCT00313729
View directory record Official record
Conditions
CNS Tumor, Adult
Interventions
temozolomide
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 120 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 6, 2019 · Synced Sep 7, 2026, 10:24 PM EDT
Recruiting No phase listed Observational

ExoLuminate Study for Early Detection of Pancreatic Cancer

NCT05625529
View directory record Official record
Conditions
Pancreas Cancer, Exosomes, Extracellular Vesicles, Pancreatic Neoplasms
Interventions
Not listed
Lead sponsor
Biological Dynamics
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 27, 2025 · Synced Sep 7, 2026, 10:24 PM EDT
Completed No phase listed Observational

Patient-reported Outcome Questionnaire for Women With Metastatic Breast Cancer

NCT01282931
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Not listed
Lead sponsor
Health Outcomes Solutions
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Winter Park, Florida
Source: ClinicalTrials.gov public record
Updated Oct 11, 2011 · Synced Sep 7, 2026, 10:24 PM EDT